GLUE (Monte Rosa Therapeutics) EPS (Basic): $-1.63 (TTM As of Mar. 2026)


GLUE Monte Rosa Therapeutics Inc GLUE
32 GF Score
Price $20.85
! 4 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics EPS (Basic)?

Monte Rosa Therapeutics GLUE +0.51% 32 EPS (Basic) is $-1.63 as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Monte Rosa Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.45. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.63.

Monte Rosa Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.45. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.63.

Monte Rosa Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.45. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.65.

During the past 12 months, Monte Rosa Therapeutics's average EPS without NRIGrowth Rate was -2556.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 40.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Monte Rosa Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 40.80% per year. The lowest was -49.20% per year. And the median was 6.95% per year.

Monte Rosa Therapeutics  (NAS:GLUE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Monte Rosa Therapeutics EPS (Basic) Related Terms

Monte Rosa Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics EPS (Basic) Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -2.96 -2.30 -2.63 -0.98 -0.46

Monte Rosa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 -0.15 -0.33 -0.70 -0.45
GLUE
32GF Score
Monte Rosa Therapeutics Inc GLUE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Monte Rosa Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-38.626-0)/83.071
=-0.46

Monte Rosa Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-44.503-0)/99.884
=-0.45

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.63 mean?
Monte Rosa Therapeutics (GLUE) has a EPS (Basic) of $-1.63 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Monte Rosa Therapeutics and its competitors.
Is Monte Rosa Therapeutics' EPS (Basic) too high?
Monte Rosa Therapeutics' current EPS (Basic) is $-1.63. Overall, Monte Rosa Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' EPS (Basic) compare to NUVB and ATAI?
Monte Rosa Therapeutics' EPS (Basic) of $-1.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current EPS (Basic) is $-1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current EPS (Basic) of $-1.63. The current EPS (Basic) is $-1.63. Monte Rosa Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current EPS (Basic) is $-1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
32GF Score

Get the complete analysis for GLUE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.85
Price